Most immuno-oncology drugs work by altering the tumor microenviro | This webinar covers how recent advances in multiplex ...

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. | On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. The first pharma to reach a ...

A new biotech has taken flight as a result of Novartis’ red-hot $12 billion acquisition of muscular dystrophy specialist Avidity Biosciences. | A new biotech has risen from the ashes of Novartis’ ...

The FDA slammed ExThera with a warning letter for deviating from the regulatory agency’s guidelines by promoting and selling ...

Thermo Fisher Scientific is launching a new test it says can help doctors avoid the “trial-and-error” approach typically used ...

A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing Thursday on how the ...

A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug conjugate has hit its dual primary survival endpoints, ...

Asahi Kasei has unveiled plans to acquire Aicuris in a deal worth 780 million euros ($920 million), marking the latest in a ...

Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as ...

Analysts consider AtaiBeckley’s MDMA candidate a “high-risk, high-reward” bet after the drug demonstrated reductions in ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | A “fairly shocking and certainly ironic twist of fate” is ending ...